Clinical Trials Logo

Clinical Trial Summary

The SARS-COV-2 virus uses a molecule on the surface of the cell to invade it and use its internal mechanisms to reproduce. Once the virus is inside, the cell significantly decreases the amount of ACE2 that it produces. ACE2 is part of the renin-angiotensin system (RAS), which is involved in maintaining blood flow and electrolyte balance. It has been shown in obese and hypertensive individuals that levels of another molecule ACE are much higher, leading to inflammation, fibrosis, vasoconstriction and high blood pressure. ACE2 has a protective effect from ACE, leading to anti-inflammatory, anti-fibrotic and vasodilating effects. After infection with the virus, the body produces too much ACE and not enough ACE2 leading to complications or morbidity. In animal models, it has been shown that aerobic exercise can increase levels of ACE2, while decreasing levels of ACE and offers protection to the cardiovascular system by keeping these two molecules balanced. In infected individuals with SARS-COV-2, it is possible that aerobic exercise could be used to protect individuals from the long term effects of the virus and lower the chance of future complications. Although the effects of exercise on the RAS have been studied significantly, ACE2 is a relatively new discovery and has not been studied as extensively in humans. The purpose of this research is to determine the effects of aerobic exercise on the RAS, specifically on ACE2 and its products to determine if it could be used as a potential treatment for individuals infected with the SARS-COV-2 virus or reduce their risk of severe complications upon infection.


Clinical Trial Description

The design of the proposed study is an intervention study, where participants are selected into either a physically active group or a sedentary group. The physically active group will be set as our control, as the physiological stress of the exercise protocol should be lower in the physically active group and limit the magnitude of the response. Both groups will be exposed to the same experimental procedure. Participants will be placed in their group based on their responses to the CSEP Get Active questionnaire. Individuals who do not accumulate less than 75 minutes of moderate to vigorous physical activity a week will be placed in the sedentary group, while those who accumulate more than 150 minutes will be placed in the active group. Participants will be requires to keep a food log for 24 hours prior to the second session. They will then be asked to mimic their dietary intake in the food log 24 hours prior to the third session. Participants will be asked to avoid anti-Inflammatory medications, alcohol and smoking 48 hours prior to any of the sessions. Participants in both groups will undergo the same testing procedure. Tests will include densitometry and a graded exercise test to measure maximum VO2 and associated parameters. Two additional exercise sessions will be conducted, one at moderate intensity and another at high intensity, and venipuncture (5 ml) will be performed before and after each of these two sessions immediately and 30 and 60 minutes post. The proposed study is a 2x2x4 repeated measures design, with analysis being conducted using a dependent groups ANOVA and Tukey's post hoc testing. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05115383
Study type Interventional
Source Western University, Canada
Contact Kyle Weiman
Phone 5196612111
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date December 2, 2021
Completion date August 31, 2022